ID   HIC1_HUMAN              Reviewed;         733 AA.
AC   Q14526; D3DTI4;
DT   02-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 5.
DT   28-JUN-2023, entry version 200.
DE   RecName: Full=Hypermethylated in cancer 1 protein;
DE            Short=Hic-1;
DE   AltName: Full=Zinc finger and BTB domain-containing protein 29;
GN   Name=HIC1; Synonyms=ZBTB29;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2), AND VARIANT GLY-725.
RX   PubMed=7585125; DOI=10.1038/nm0695-570;
RA   Wales M.M., Biel M.A., el Deiry W., Nelkin B.D., Issa J.-P., Cavenee W.K.,
RA   Kuerbitz S.J., Baylin S.B.;
RT   "p53 activates expression of HIC-1, a new candidate tumour suppressor gene
RT   on 17p13.3.";
RL   Nat. Med. 1:570-577(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   SELF-ASSOCIATION.
RX   PubMed=10611298; DOI=10.1073/pnas.96.26.14831;
RA   Deltour S., Guerardel C., Leprince D.;
RT   "Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a
RT   general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1
RT   and gammaFBP-B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:14831-14836(1999).
RN   [5]
RP   ALTERNATIVE SPLICING, INTERACTION WITH HIC2, AND SUBCELLULAR LOCATION.
RX   PubMed=11554746; DOI=10.1006/bbrc.2001.5624;
RA   Deltour S., Pinte S., Guerardel C., Leprince D.;
RT   "Characterization of HRG22, a human homologue of the putative tumor
RT   suppressor gene HIC1.";
RL   Biochem. Biophys. Res. Commun. 287:427-434(2001).
RN   [6]
RP   FUNCTION, SELF-ASSOCIATION, AND INTERACTION WITH CTBP1.
RX   PubMed=12052894; DOI=10.1128/mcb.22.13.4890-4901.2002;
RA   Deltour S., Pinte S., Guerardel C., Wasylyk B., Leprince D.;
RT   "The human candidate tumor suppressor gene HIC1 recruits CtBP through a
RT   degenerate GLDLSKK motif.";
RL   Mol. Cell. Biol. 22:4890-4901(2002).
RN   [7]
RP   FUNCTION, DNA-BINDING, AND MUTAGENESIS OF CYS-540.
RX   PubMed=15231840; DOI=10.1074/jbc.m401610200;
RA   Pinte S., Stankovic-Valentin N., Deltour S., Rood B.R., Guerardel C.,
RA   Leprince D.;
RT   "The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a
RT   sequence-specific transcriptional repressor: definition of its consensus
RT   binding sequence and analysis of its DNA binding and repressive
RT   properties.";
RL   J. Biol. Chem. 279:38313-38324(2004).
RN   [8]
RP   FUNCTION.
RX   PubMed=16269335; DOI=10.1016/j.cell.2005.08.011;
RA   Chen W.Y., Wang D.H., Yen R.C., Luo J., Gu W., Baylin S.B.;
RT   "Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent
RT   DNA-damage responses.";
RL   Cell 123:437-448(2005).
RN   [9]
RP   FUNCTION.
RX   PubMed=16690027; DOI=10.1016/j.bbrc.2006.04.052;
RA   Briones V.R., Chen S., Riegel A.T., Lechleider R.J.;
RT   "Mechanism of fibroblast growth factor-binding protein 1 repression by TGF-
RT   beta.";
RL   Biochem. Biophys. Res. Commun. 345:595-601(2006).
RN   [10]
RP   FUNCTION IN WNT SIGNALING, AND INTERACTION WITH TCF7L2.
RX   PubMed=16724116; DOI=10.1038/sj.emboj.7601147;
RA   Valenta T., Lukas J., Doubravska L., Fafilek B., Korinek V.;
RT   "HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to
RT   the nuclear bodies.";
RL   EMBO J. 25:2326-2337(2006).
RN   [11]
RP   INTERACTION WITH CTBP1 AND CTBP2, AND MUTAGENESIS OF LEU-244.
RX   PubMed=16762039; DOI=10.1111/j.1742-4658.2006.05301.x;
RA   Stankovic-Valentin N., Verger A., Deltour-Balerdi S., Quinlan K.G.,
RA   Crossley M., Leprince D.;
RT   "A L225A substitution in the human tumour suppressor HIC1 abolishes its
RT   interaction with the corepressor CtBP.";
RL   FEBS J. 273:2879-2890(2006).
RN   [12]
RP   SUMOYLATION AT LYS-333, ACETYLATION AT LYS-333, AND MUTAGENESIS OF LYS-333;
RP   GLU-335 AND PRO-336.
RX   PubMed=17283066; DOI=10.1128/mcb.01098-06;
RA   Stankovic-Valentin N., Deltour S., Seeler J., Pinte S., Vergoten G.,
RA   Guerardel C., Dejean A., Leprince D.;
RT   "An acetylation/deacetylation-SUMOylation switch through a phylogenetically
RT   conserved psiKXEP motif in the tumor suppressor HIC1 regulates
RT   transcriptional repression activity.";
RL   Mol. Cell. Biol. 27:2661-2675(2007).
RN   [13]
RP   RETRACTED PAPER.
RX   PubMed=17213307; DOI=10.1073/pnas.0610590104;
RA   Zhang Q., Wang S.Y., Fleuriel C., Leprince D., Rocheleau J.V., Piston D.W.,
RA   Goodman R.H.;
RT   "Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor
RT   complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:829-833(2007).
RN   [14]
RP   RETRACTION NOTICE OF PUBMED:17213307.
RX   PubMed=25646486; DOI=10.1073/pnas.1501052112;
RA   Zhang Q., Wang S.Y., Fleuriel C., Dominique L., Rocheleau J.V.,
RA   Piston D.W., Goodman R.H.;
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E819-E819(2015).
RN   [15]
RP   FUNCTION.
RX   PubMed=18347096; DOI=10.1101/gad.1640908;
RA   Briggs K.J., Corcoran-Schwartz I.M., Zhang W., Harcke T., Devereux W.L.,
RA   Baylin S.B., Eberhart C.G., Watkins D.N.;
RT   "Cooperation between the Hic1 and Ptch1 tumor suppressors in
RT   medulloblastoma.";
RL   Genes Dev. 22:770-785(2008).
RN   [16]
RP   ERRATUM OF PUBMED:18347096.
RA   Briggs K.J., Corcoran-Schwartz I.M., Zhang W., Harcke T., Devereux W.L.,
RA   Baylin S.B., Eberhart C.G., Watkins D.N.;
RL   Genes Dev. 22:1410-1410(2008).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH ARID1A.
RX   PubMed=19486893; DOI=10.1016/j.bbrc.2009.05.115;
RA   Van Rechem C., Boulay G., Leprince D.;
RT   "HIC1 interacts with a specific subunit of SWI/SNF complexes,
RT   ARID1A/BAF250A.";
RL   Biochem. Biophys. Res. Commun. 385:586-590(2009).
RN   [18]
RP   FUNCTION.
RX   PubMed=19525223; DOI=10.1074/jbc.m109.022350;
RA   Van Rechem C., Rood B.R., Touka M., Pinte S., Jenal M., Guerardel C.,
RA   Ramsey K., Monte D., Begue A., Tschan M.P., Stephan D.A., Leprince D.;
RT   "Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene
RT   of HIC1 (hypermethylated in cancer 1).";
RL   J. Biol. Chem. 284:20927-20935(2009).
RN   [19]
RP   FUNCTION, INTERACTION WITH MTA1 AND MBD3, AND MUTAGENESIS OF LYS-333;
RP   GLU-335 AND PRO-336.
RX   PubMed=20547755; DOI=10.1128/mcb.00582-09;
RA   Van Rechem C., Boulay G., Pinte S., Stankovic-Valentin N., Guerardel C.,
RA   Leprince D.;
RT   "Differential regulation of HIC1 target genes by CtBP and NuRD, via an
RT   acetylation/SUMOylation switch, in quiescent versus proliferating cells.";
RL   Mol. Cell. Biol. 30:4045-4059(2010).
RN   [20]
RP   FUNCTION.
RX   PubMed=20154726; DOI=10.1038/onc.2010.12;
RA   Zhang W., Zeng X., Briggs K.J., Beaty R., Simons B., Chiu Yen R.W.,
RA   Tyler M.A., Tsai H.C., Ye Y., Gesell G.S., Herman J.G., Baylin S.B.,
RA   Watkins D.N.;
RT   "A potential tumor suppressor role for Hic1 in breast cancer through
RT   transcriptional repression of ephrin-A1.";
RL   Oncogene 29:2467-2476(2010).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-237; SER-248 AND SER-366, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Transcriptional repressor (PubMed:12052894, PubMed:15231840).
CC       Recognizes and binds to the consensus sequence '5-
CC       [CG]NG[CG]GGGCA[CA]CC-3' (PubMed:15231840). May act as a tumor
CC       suppressor (PubMed:20154726). Involved in development of head, face,
CC       limbs and ventral body wall (By similarity). Involved in down-
CC       regulation of SIRT1 and thereby is involved in regulation of p53/TP53-
CC       dependent apoptotic DNA-damage responses (PubMed:16269335). The
CC       specific target gene promoter association seems to be depend on
CC       corepressors, such as CTBP1 or CTBP2 and MTA1 (PubMed:12052894,
CC       PubMed:20547755). In cooperation with MTA1 (indicative for an
CC       association with the NuRD complex) represses transcription from
CC       CCND1/cyclin-D1 and CDKN1C/p57Kip2 specifically in quiescent cells
CC       (PubMed:20547755). Involved in regulation of the Wnt signaling pathway
CC       probably by association with TCF7L2 and preventing TCF7L2 and CTNNB1
CC       association with promoters of TCF-responsive genes (PubMed:16724116).
CC       Seems to repress transcription from E2F1 and ATOH1 which involves
CC       ARID1A, indicative for the participation of a distinct SWI/SNF-type
CC       chromatin-remodeling complex (PubMed:18347096, PubMed:19486893).
CC       Probably represses transcription of ACKR3, FGFBP1 and EFNA1
CC       (PubMed:16690027, PubMed:19525223, PubMed:20154726).
CC       {ECO:0000250|UniProtKB:Q9R1Y5, ECO:0000269|PubMed:12052894,
CC       ECO:0000269|PubMed:15231840, ECO:0000269|PubMed:16269335,
CC       ECO:0000269|PubMed:16690027, ECO:0000269|PubMed:16724116,
CC       ECO:0000269|PubMed:18347096, ECO:0000269|PubMed:19486893,
CC       ECO:0000269|PubMed:19525223, ECO:0000269|PubMed:20154726,
CC       ECO:0000269|PubMed:20547755}.
CC   -!- SUBUNIT: Self-associates (PubMed:10611298, PubMed:12052894). Interacts
CC       with HIC2 (PubMed:11554746). Interacts with CTBP1 and CTBP2
CC       (PubMed:12052894, PubMed:16762039). Interacts with TCF7L2 and ARID1A
CC       (PubMed:16724116, PubMed:19486893). Interacts with MTA1 and MBD3;
CC       indicative for an association with the NuRD complex (PubMed:20547755).
CC       Interacts with SIRT1 (By similarity). {ECO:0000250|UniProtKB:Q9R1Y5,
CC       ECO:0000269|PubMed:10611298, ECO:0000269|PubMed:11554746,
CC       ECO:0000269|PubMed:12052894, ECO:0000269|PubMed:16724116,
CC       ECO:0000269|PubMed:16762039, ECO:0000269|PubMed:19486893,
CC       ECO:0000269|PubMed:20547755}.
CC   -!- INTERACTION:
CC       Q14526; O14497: ARID1A; NbExp=2; IntAct=EBI-2507362, EBI-637887;
CC       Q14526; Q13363: CTBP1; NbExp=2; IntAct=EBI-2507362, EBI-908846;
CC       Q14526; P56545: CTBP2; NbExp=2; IntAct=EBI-2507362, EBI-741533;
CC       Q14526; Q9NQB0: TCF7L2; NbExp=6; IntAct=EBI-2507362, EBI-924724;
CC       Q14526; O88712: Ctbp1; Xeno; NbExp=10; IntAct=EBI-2507362, EBI-604547;
CC       Q14526; P56546: Ctbp2; Xeno; NbExp=2; IntAct=EBI-2507362, EBI-1384883;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11554746}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=Q14526-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14526-2; Sequence=VSP_006826;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed with highest levels found in
CC       lung, colon, prostate, thymus, testis and ovary. Expression is absent
CC       or decreased in many tumor cells.
CC   -!- DOMAIN: The BTB domain inhibits the binding to a single consensus
CC       binding site, but mediates cooperative binding to multiple binding
CC       sites.
CC   -!- PTM: Acetylated on several residues, including Lys-333. Lys-333 is
CC       deacetylated by SIRT1. {ECO:0000269|PubMed:17283066}.
CC   -!- PTM: Sumoylated on Lys-333 by a PIAS family member, which enhances
CC       interaction with MTA1, positively regulates transcriptional repression
CC       activity and is enhanced by HDAC4. {ECO:0000269|PubMed:17283066}.
CC   -!- MISCELLANEOUS: The HIC1 gene is frequently found epigenetically
CC       silenced or deleted in different types of solid tumors.
CC   -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein
CC       family. Hic subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/40819/HIC1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L41919; AAD09201.1; -; Genomic_DNA.
DR   EMBL; AC090617; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW90562.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90563.1; -; Genomic_DNA.
DR   CCDS; CCDS42229.1; -. [Q14526-1]
DR   CCDS; CCDS42230.1; -. [Q14526-2]
DR   RefSeq; NP_001091672.1; NM_001098202.1. [Q14526-1]
DR   RefSeq; NP_006488.2; NM_006497.3. [Q14526-2]
DR   AlphaFoldDB; Q14526; -.
DR   SMR; Q14526; -.
DR   BioGRID; 109337; 38.
DR   CORUM; Q14526; -.
DR   ELM; Q14526; -.
DR   IntAct; Q14526; 13.
DR   MINT; Q14526; -.
DR   STRING; 9606.ENSP00000314080; -.
DR   GlyGen; Q14526; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q14526; -.
DR   PhosphoSitePlus; Q14526; -.
DR   BioMuta; HIC1; -.
DR   DMDM; 296439502; -.
DR   jPOST; Q14526; -.
DR   MassIVE; Q14526; -.
DR   PaxDb; Q14526; -.
DR   PeptideAtlas; Q14526; -.
DR   ProteomicsDB; 60028; -. [Q14526-1]
DR   ProteomicsDB; 60029; -. [Q14526-2]
DR   TopDownProteomics; Q14526-1; -. [Q14526-1]
DR   Antibodypedia; 5361; 314 antibodies from 32 providers.
DR   DNASU; 3090; -.
DR   Ensembl; ENST00000322941.3; ENSP00000314080.3; ENSG00000177374.13. [Q14526-1]
DR   Ensembl; ENST00000399849.4; ENSP00000382742.2; ENSG00000177374.13. [Q14526-2]
DR   Ensembl; ENST00000619757.5; ENSP00000477858.1; ENSG00000177374.13. [Q14526-2]
DR   GeneID; 3090; -.
DR   KEGG; hsa:3090; -.
DR   MANE-Select; ENST00000619757.5; ENSP00000477858.1; NM_006497.4; NP_006488.2. [Q14526-2]
DR   UCSC; uc002fty.5; human. [Q14526-1]
DR   AGR; HGNC:4909; -.
DR   CTD; 3090; -.
DR   DisGeNET; 3090; -.
DR   GeneCards; HIC1; -.
DR   HGNC; HGNC:4909; HIC1.
DR   HPA; ENSG00000177374; Low tissue specificity.
DR   MalaCards; HIC1; -.
DR   MIM; 603825; gene.
DR   neXtProt; NX_Q14526; -.
DR   OpenTargets; ENSG00000177374; -.
DR   Orphanet; 531; Miller-Dieker syndrome.
DR   PharmGKB; PA29282; -.
DR   VEuPathDB; HostDB:ENSG00000177374; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000161725; -.
DR   HOGENOM; CLU_015352_1_0_1; -.
DR   InParanoid; Q14526; -.
DR   OrthoDB; 1378030at2759; -.
DR   PhylomeDB; Q14526; -.
DR   TreeFam; TF333488; -.
DR   PathwayCommons; Q14526; -.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   SignaLink; Q14526; -.
DR   SIGNOR; Q14526; -.
DR   BioGRID-ORCS; 3090; 9 hits in 1204 CRISPR screens.
DR   ChiTaRS; HIC1; human.
DR   GeneWiki; HIC1; -.
DR   GenomeRNAi; 3090; -.
DR   Pharos; Q14526; Tbio.
DR   PRO; PR:Q14526; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q14526; protein.
DR   Bgee; ENSG00000177374; Expressed in cardiac muscle of right atrium and 123 other tissues.
DR   ExpressionAtlas; Q14526; baseline and differential.
DR   Genevisible; Q14526; HS.
DR   GO; GO:0000785; C:chromatin; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043517; P:positive regulation of DNA damage response, signal transduction by p53 class mediator; ISS:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 4.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR24394:SF16; HYPERMETHYLATED IN CANCER 1 PROTEIN; 1.
DR   PANTHER; PTHR24394; ZINC FINGER PROTEIN; 1.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF00096; zf-C2H2; 4.
DR   SMART; SM00225; BTB; 1.
DR   SMART; SM00355; ZnF_C2H2; 5.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 3.
DR   SUPFAM; SSF54695; POZ domain; 1.
DR   PROSITE; PS50097; BTB; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 5.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 5.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Developmental protein; DNA-binding;
KW   Isopeptide bond; Metal-binding; Methylation; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation;
KW   Wnt signaling pathway; Zinc; Zinc-finger.
FT   CHAIN           1..733
FT                   /note="Hypermethylated in cancer 1 protein"
FT                   /id="PRO_0000046942"
FT   DOMAIN          47..110
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   ZN_FING         439..459
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         509..529
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         537..557
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         565..585
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         593..613
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          154..315
FT                   /note="Mediates HDAC-dependent transcriptional repression"
FT   REGION          189..209
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          241..421
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          241..247
FT                   /note="Interaction with CTBP1"
FT   COMPBIAS        189..205
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        265..290
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        347..361
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         159
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1Y5"
FT   MOD_RES         237
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         248
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         333
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:17283066"
FT   MOD_RES         366
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         704
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1Y5"
FT   CROSSLNK        333
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT   VAR_SEQ         1..19
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006826"
FT   VARIANT         725
FT                   /note="R -> G (in dbSNP:rs1063317)"
FT                   /evidence="ECO:0000269|PubMed:7585125"
FT                   /id="VAR_063109"
FT   MUTAGEN         244
FT                   /note="L->A: Abolishes interaction with CTBP1 and CTBP2.
FT                   Impairs transcriptional repression."
FT                   /evidence="ECO:0000269|PubMed:16762039"
FT   MUTAGEN         333
FT                   /note="K->Q: Mimicks acetylation. Impairs interaction with
FT                   RBBP4 and MTA1 and no effect on interaction with CTBP2.
FT                   Reduces transcriptional repression."
FT                   /evidence="ECO:0000269|PubMed:17283066,
FT                   ECO:0000269|PubMed:20547755"
FT   MUTAGEN         333
FT                   /note="K->R: Abolishes sumoylation; impairs transcriptional
FT                   repression activity."
FT                   /evidence="ECO:0000269|PubMed:17283066,
FT                   ECO:0000269|PubMed:20547755"
FT   MUTAGEN         335
FT                   /note="E->A: Impairs transcriptional repression activity.
FT                   Decreases interaction with MTA1."
FT                   /evidence="ECO:0000269|PubMed:17283066,
FT                   ECO:0000269|PubMed:20547755"
FT   MUTAGEN         336
FT                   /note="P->A: Impairs K-333 acetylation; no effect on
FT                   sumoylation. Decreases interaction with MTA1."
FT                   /evidence="ECO:0000269|PubMed:17283066,
FT                   ECO:0000269|PubMed:20547755"
FT   MUTAGEN         540
FT                   /note="C->S: Abolishes repression activity."
FT                   /evidence="ECO:0000269|PubMed:15231840"
FT   CONFLICT        190
FT                   /note="P -> R (in Ref. 1; AAD09201)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   733 AA;  76508 MW;  6DDD0F49C4E490D3 CRC64;
     MTFPEADILL KSGECAGQTM LDTMEAPGHS RQLLLQLNNQ RTKGFLCDVI IVVQNALFRA
     HKNVLAASSA YLKSLVVHDN LLNLDHDMVS PAVFRLVLDF IYTGRLADGA EAAAAAAVAP
     GAEPSLGAVL AAASYLQIPD LVALCKKRLK RHGKYCHLRG GGGGGGGYAP YGRPGRGLRA
     ATPVIQACYP SPVGPPPPPA AEPPSGPEAA VNTHCAELYA SGPGPAAALC ASERRCSPLC
     GLDLSKKSPP GSAAPERPLA ERELPPRPDS PPSAGPAAYK EPPLALPSLP PLPFQKLEEA
     APPSDPFRGG SGSPGPEPPG RPDGPSLLYR WMKHEPGLGS YGDELGRERG SPSERCEERG
     GDAAVSPGGP PLGLAPPPRY PGSLDGPGAG GDGDDYKSSS EETGSSEDPS PPGGHLEGYP
     CPHLAYGEPE SFGDNLYVCI PCGKGFPSSE QLNAHVEAHV EEEEALYGRA EAAEVAAGAA
     GLGPPFGGGG DKVAGAPGGL GELLRPYRCA SCDKSYKDPA TLRQHEKTHW LTRPYPCTIC
     GKKFTQRGTM TRHMRSHLGL KPFACDACGM RFTRQYRLTE HMRIHSGEKP YECQVCGGKF
     AQQRNLISHM KMHAVGGAAG AAGALAGLGG LPGVPGPDGK GKLDFPEGVF AVARLTAEQL
     SLKQQDKAAA AELLAQTTHF LHDPKVALES LYPLAKFTAE LGLSPDKAAE VLSQGAHLAA
     GPDGRTIDRF SPT
//
